ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--()--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • Leerink Partners 5th Annual Global Healthcare Conference
    2:40 pm ET, February 10
  • RBC Capital Markets Global Healthcare Conference
    11:30 am ET, February 23
  • Cowen and Company 36th Annual Health Care Conference
    9:20 am ET, March 8

The webcasts will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

Contacts

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

Recent Stories

RSS feed for ImmunoGen, Inc.

ImmunoGen, Inc.